Concise asymmetric synthesis of configurationally stable 4-trifluoromethyl thalidomide

Future Medicinal Chemistry

Volumn 1, Issue 5, 2009, Pages 897-908

  Soloshonok, Vadim A ^a   Yamada, Takeshi ^b   Sakaguchi, Kazuhiko ^b   Ohfune, Yasufumi ^b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b Osaka Prefecture University   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 TRIFLUOROMETHYL ACRYLIC ACID; 3 TRIFLUOROMETHYL PYROGLUTAMIC ACID; 4 TRIFLUOROMETHYL THALIDOMIDE; ACRYLIC ACID DERIVATIVE; GLUTAMIC ACID DERIVATIVE; THALIDOMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; ASYMMETRIC SYNTHESIS; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRICITY; MICHAEL ADDITION; PRIORITY JOURNAL;

PYRROLIDONECARBOXYLIC ACID; STEREOISOMERISM; THALIDOMIDE;

EID: 77953372156     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.63     Document Type: Article

References (80)

1. Eger K, Jalalian B, Verspohl EJ, Lupke NP. Synthesis, central nervous system activity and teratogenicity of a homothalidomide Arzneim. Forsch. 40, 1073-1075 (1990).
2. Folkman J. Tumor angiogenesis: a possible control point in tumor growth. Ann. Intern. Med. 82, 96-100 (1975).
3. Sampio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor αproduction by stimulated human monocytes J. Exp. Med. 173, 699-703 (1991).
4. Moreira, AL, Sampio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor αby enhancing mRNA degradation J. Exp. Med. 177, 1675-1680 (1993).
5. Musto P, D'Auria F, Pietrantuono G et al. Role of thalidomide in previously untreated patients with multiple myeloma. Expert Rev. Anticancer Ther. 8, 1569-1580 (2008).
6. Hashimoto Y. Thalidomide as a multitemplate for development of biologically active compounds. Arch. Pharm. Chem. Life Sci. 341, 536-547 (2008).
7. Palumbo A, Facon T, Sonneveld P et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111, 3968-3977 (2008).
8. Walker SL, Waters MF, Lockwood DN. The role of thalidomide in the management of erythema nodosum leprosum. Lepr. Rev. 78, 197-215 (2007).
9. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400 (2004).
10. Kumar S, Rajkumar SV. Thalidomide and dexamethasone: therapy for multiple myeloma. Expert Rev. Anticancer Ther. 5 759-766 (2005).
11. Kumar S, Anderson KC. Drug insight: thalidomide as a treatment for multiple myeloma. Nat. Clin. Pract. Oncol. 2, 262-270 (2005).
12. Eigler A, Sinha B, Hartmann G, Endres S. Taming TNF: strategies to restrain this proinflammatory cytokine. Immunology Today 18, 487-492 (1997).
13. Teo SK, Resztak KE, Scheffler MA et al. Thalidomide in the treatment of leprosy. Microbes Infect. 4, 1193-1202 (2002).
14. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Volcker HE. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefe's Arch. Clin. Exp. Ophthalmol. 236, 461-466 (1998).
15. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer 4, 314-322 (2004).
16. Singhal S, Mehta J. Thalidomide in cancer: potential uses and limitations. BioDrugs 15, 163-172 (2001).
17. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin. Pharmacol. Ther. 6, 303-306 (1965).
18. Blaschke G, Klaft HP, Fickentscher K, Koehler F. Chromatographic racemic separation of thalidomide and teratogenic activity of its enantiomers. Arzneim. Forsch. 29, 1640-1642 (1979).
19. Hoglund P, Eriksson T, Bjorkman S. A double-blind study of the sedative effects of the thalidomide enantiomers in humans. J. Pharmacokinet. Biopharm. 26, 363-383 (1998).
20. Eriksson T, Bjorkman S, Roth B, Fyge A, Hoglund P. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 7, 44-52 (1995).
21. Wintersk W, Frankus E. Thalidomide enantiomers. Lancet 339, 365 (1992).
22. Eriksson T, Bjorkman S, Hoglund P. Clinical pharmacology of thalidomide. Eur. J. Clin. Pharmacol. 57, 365-376 (2001).
23. Wnendt S, Finkam M, Winter W, Ossing J, Rabbe G, Zwingenberger K. Enantioselective inhibition of TNF-αrelease by thalidomide and thalidomide-analogs. Chirality 8, 390-396 (1996).
24. Knoche B, Blaschke G. Investigations on the in vitro racemization of thalidomide by high-performance liquid chromatography. J. Chromatogr. 2, 235-240 (1994).
25. Chung F, Palmer BD, Muller GW et al. Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Oncol. Res. 14, 75-82 (2003).
26. Miyachi H, Kolso Y, Shirai R, Niwayama S, Liu JO, Hashimoto Y. Tumor necrosis factor-αproduction enhancing activity of substituted 3́-methylthalidomide: influence of substituents at the phthaloyl moiety on the activity and stereoselectivity. Chem. Pharm. Bull. 46, 1165-1168 (1998).
27. Buech HP, Omlor G, Knabe J. Stereoselective differences of central nervous systemdepressive action of a homologous series of 3-alkyl-thalidomide analysis. Arzneim. Forsch. 40, 32-36 (1990).
28. Knabe J, Omlor G. Synthesis of racemates and enantiomers of 3-alkylthalidomide analogs and determination of their absolute configuration. Arch. Der Pharmazie. 322, 499-505 (1989).
29. Muller GW, Chen RS. Preparation of 4-amino-2-(3-methyl-2,6- dioxopiperidin-3- yl)-isoindole-1,3-dione and compositions thereof for pharmaceutical applications. PCT Int. Appl. 56 (2006).
30. Osipov SN, Tsouker P, Hennig L, Burger K. 3-trifluoromethyl- and 3-difluoromethylthalidomides. Tetrahedron, 60, 271-274 (2004).
31. Takeuchi Y, Shiragami T, Kimura K, Suzuki E, Shibata N. (R)- and (S)-3- fluorothalidomides: isosteric analogs of thalidomide. Org. Lett. 1, 1571-1573 (1999).
32. Corot C, Port M, Gautheret T, Williard X. Diagnostic compounds comprising a scaffold coupled to a signal entity for medical imaging diagnostic. US Pat. Appl. Publ. 17 (2005).
33. Luzzio FA, Thomas EM, Figg WD. Thalidomide metabolites and analogs. Part 2: cyclic derivatives of 2-N-phthalimido- 2S,3S (3-hydroxy) ornithine. Tetrahedron Lett. 41, 7151-7155 (2000).
34. Yamada T, Okada T, Sakaguchi K, Ohfune Y, Ueki H, Soloshonok VA. Efficient asymmetric synthesis of novel 4-substituted and configurationally stable analogs of thalidomide. Org Lett. 8, 5625-5628 (2006)
35. Soloshonok VA, Gerus II, Yagupolskii YL, Kukhar VP. Fluorine-containing amino acids. III. α-trifluoromethyl-α-amino acids. Zh. Org. Khim. 23, 2308-2313 (1987).
36. Soloshonok VA, Avilov DV, Kukhar VP et al. Asymmetric aldol reactions of chiral Ni(II)-complex of glycine with aldehydes. Stereodivergent synthesis of syn-(2S)- and syn-(2R)-β-alkylserines. Tetra. Asymm. 6, 1741-1756 (1995).
37. Soloshonok VA, Avilov DV, Kukhar VP Highly diastereoselective asymmetric aldol reactions of chiral Ni(II)-complex of glycine with trifluoromethyl ketones. Tetra. Asymm. 7, 1547-1550 (1996).
38. Basiuk VA, Gromovoy TY, Chuiko AA, Soloshonok VA, Kukhar VP. A novel approach to the synthesis of symmetric optically active 2,5-dioxopiperazines. Synthesis 5, 449-451 (1992).
39. Soloshonok VA, Kirilenko AG, Kukhar VP, Resnati G. Transamination of fluorinated α-keto carboxylic esters. A biomimetic approach to β-polyfluoroalkyl-β-amino acids. Tetrahedron Lett. 34, 3621-3624 (1993).
40. Soloshonok VA, Ono T. The effect of substituents on the feasibility of azomethine-azomethine isomerization: new synthetic opportunities for biomimetic transamination. Tetrahedron 52, 14701-14712 (1996).
41. Bravo P, Farina A, Frigerio M, Valdo Meille S, Viani F, Soloshonok VA. New fluorinated chiral synthons. Tetra. Asymm. 5, 987-1004 (1994).
42. Soloshonok VA, Hayashi T, Ishikawa K, Nagashima N. Highly diastereoselective aldol reaction of fluoroalkyl aryl ketones with methyl isocyanoacetate catalyzed by silver(I)/triethylamine. Tetrahedron Lett. 35, 1055-1058 (1994).
43. Ohkura H, Berbasov DO, Soloshonok VA. Simple and highly diastereoselective synthesis of trifluoromethyl-containing myosmines via reaction between 2-(aminomethyl)pyridine and 1,1,1,5,5,5-hexafluoro-2,4- pentanedione. Tetrahedron Lett. 44, 2417-2420 (2003).
44. Bravo P, Farina A, Kukhar VP et al. Stereoselective additions of α-lithiated alkyl p-tolylsulfoxides to N-PMP fluoroalkyl aldimines. An efficient approach to enantiomerically pure fluoro-amino compounds J. Org. Chem. 62, 3424-3425 (1997).
45. Soloshonok VA, Kacharov AD, Avilov DV, Ishikawa K, Nagashima N, Hayashi T. Transition metal/base-catalyzed aldol reactions of methyl α-isocyanoacetate with prochiral ketones, a straightforward approach to stereochemically defined β,β-disubstituted-β-hydroxy-α- amino acids. Scope and limitations. J. Org. Chem. 62, 3470-3479 (1997).
46. Soloshonok VA, Kacharov AD, Hayashi T. Gold(I)-catalyzed asymmetric aldol reactions of isocyanoacetic acid derivatives with fluoroaryl aldehydes. Tetrahedron 52, 245-254 (1996).
47. Soloshonok VA, Kukhar VP, Biomimetic transamination of α-keto perfluorocarboxylic esters. an efficient preparative synthesis of β,β,β-trifluoroalanine. Tetrahedron 53, 8307-8314 (1997).
48. Soloshonok VA, Yagupolskii YL, Kukhar VP. Fluorine-containing amino acids. V. imines of trifluoropyruvic acid in the synthesis of n-substituted trifluoroalanines. Zh. Org. Khim. 24, 1638-1644 (1988).
49. Tang X, Soloshonok VA, Hruby VJ. Convenient asymmetric synthesis of enantiomerically pure 2́6́-dimethyltyrosine (DMT) via alkylation of chiral nucleophilic glycine equivalent. Tetra. Asymm. 11, 2917-2925 (2000).
50. Soloshonok VA, Tang X, Hruby VJ. Large-scale asymmetric synthesis of novel sterically constrained 2́,6́-dimethyl- and α,2́,6́-trimethyltyrosine and -phenylalanine derivatives via alkylation of chiral equivalents of nucleophilic glycine and alanine. Tetrahedron 57, 6375-6382 (2001).
51. Ellis TK, Martin CH, Tsai GM, Ueki H, Soloshonok VA. Efficient synthesis of sterically constrained symmetrically α,α-disubstituted α-amino acids under operationally convenient conditions. J. Org. Chem. 68, 6208-6214 (2003).
52. Qiu W, Gu X, Soloshonok VA, Carducci MD, Hruby VJ. Stereoselective synthesis of conformationally constrained reverse turn dipeptide mimetics. Tetrahedron Lett. 42, 145-148 (2001).
53. Cai M, Cai C, Mayorov AV et al. Biological and conformational study of β-substituted prolines in MT-II template: steric effects leading to human MC5 receptor selectivity. J. Peptide Res. 63, 116-131 (2004).
54. Soloshonok VA, Tang X, Hruby VJ, Meervelt LV. asymmetric synthesis of α,β-dialkyl-αphenylalanines via direct alkylation of chiral alanine derivative with racemic α-alkylbenzylbromides. A case of high enantiomer differentiation at room temperature. Org. Lett. 3, 341-343 (2001).
55. Soloshonok VA, Hayashi T. Gold(I)-catalyzed asymmetric aldol reaction of methyl isocyanoacetate with fluorinated benzaldehydes. Tetrahedron Lett. 35, 2713-2716 (1994).
56. Soloshonok VA, Avilov DV, Kukhar VP, Meervelt LV, Mischenko N. An efficient asymmetric synthesis of (2S,3S)-3- trifluoromethylpyroglutamic acid. Tetrahedron Lett. 38, 4903-4904 (1997).
57. Soloshonok VA, Cai C, Hruby VJ. Asymmetric michael addition reactions of chiral Ni(II) complex of glycine with N-(enoyl)oxazolidinones: improved reactivity and stereochemical outcome. Tetrahedron 55, 12031-12044 (1999).
58. Soloshonok VA, Cai C, Hruby VJ, Meervelt LV. Asymmetric synthesis of novel highly sterically constrained (2S,3S)-3-methyl-3-trifluoromethyl- and (2S,3S,4R)-3-trifluoromethyl-4- methylpyroglutamic acids. Tetrahedron 55, 12045-12058 (1999).
59. Ueki H, Ellis TK, Martin CH, Bolene SB, Boettiger TU, Soloshonok VA. Improved synthesis of proline derived Ni(II)-complexes of glycine, a versatile chiral equivalents of nucleophilic glycine for general asymmetric synthesis of α-amino acids. J. Org. Chem. 68, 7104-7107 (2003).
60. Soloshonok VA, Cai C, Yamada T, Ueki H, Ohfune Y, Hruby VJ. Michael addition reactions between chiral equivalents of a nucleophilic glycine and (S)- or (R)-3-(Eenoyl)- 4-phenyl-1,3-oxazolidin-2-ones as a general method for efficient preparation of β-substituted pyroglutamic acids. Case of topographically controlled stereoselectivity. J. Am. Chem. Soc. 127, 15296-15303 (2005).
61. Soloshonok VA. Highly diastereoselective michael addition reactions between nucleophilic glycine equivalents and β-substituted-α,β- unsaturated carboxylic acid derivatives; a general approach to the stereochemically defined and sterically γ-constrained α-amino acids. Current Org. Chem. 6, 341-364 (2002).
62. Soloshonok VA, Belokon YN, Kuzmina NA et al. Asymmetric synthesis of phosphorus analogs of dicarboxylic α-amino acids. J. Chem. Soc. Perkin Trans. 1, 1525-1529 (1992).
63. Soloshonok VA, Cai C, Hruby VJ. (S)- or (R)-N-(E-enoyl)-4-phenyl-1,3- oxazolidin-2- ones: ideal michael acceptors to afford a virtually complete control of simple and face diastereoselectivity in addition reactions with glycine derivatives. Org. Lett. 2, 747-750 (2000).
64. Soloshonok VA, Cai C, Hruby VJ. Toward design of a practical methodology for stereocontrolled synthesis of γ-constrained pyroglutamic acids and related compounds. virtually complete control of simple diastereoselectivity in the michael addition reactions of glycine Ni(II) complexes with N-(enoyl)oxazolidinones. Tetrahedron Lett. 41, 135-139 (2000).
65. Soloshonok VA, Cai C, Hruby VJ. A unique case of face diastereoselectivity in the michael addition reactions between Ni(II)-complexes of glycine and chiral 3-(E-enoyl)-1,3-oxazolidin- 2-ones. Tetrahedron Lett. 41, 9645-9649 (2000).
66. Soloshonok VA, Cai C, Hruby VJ. Asymmetric michael addition reactions of chiral Ni(II) complex of glycine with N-(enoyl)oxazolidinones: improved reactivity and stereochemical outcome. Tetra. Asymm. 10, 4265-4269 (1999).
67. Soloshonok VA, Ueki H, Ellis TK. New generation of nucleophilic glycine equivalents. Tetrahedron Lett. 46, 941-944 (2005).
68. Soloshonok VA, Ueki H, Ellis TK, Yamada T, Ohfune Y. Application of modular nucleophilic glycine equivalents for truly practical asymmetric synthesis of β-substituted pyroglutamic acids. Tetrahedron Lett. 46, 1107-1110 (2005).
69. Soloshonok VA, Ellis TK. Design and synthesis of a new generation of 'NH' Ni(II) complexes of glycine schiff bases and their unprecedented C-H vs. N-H chemoselectivity in the alkyl halide alkylations and Michael addition reactions. Synlett 533-538 (2006).
70. Ellis TK, Ueki H, Yamada T, Ohfune Y, Soloshonok VA. The design, synthesis and evaluation of a new generation of modular nucleophilic glycine equivalents for the efficient synthesis of sterically constrained α-amino acids. J. Org. Chem. 71, 8572-8578 (2006).
71. Soloshonok VA, Ueki H, Jiang C, Cai C, Hruby VJ. A convenient, room temperatureorganic base protocol for preparing chiral N-(enoyl)-1,3-oxazolidine- 2-ones. Helv. Chim. Acta. 85, 3616-3623 (2002).
72. Yamazaki T, Shinohara N, Kitazume T, Sato S. Michael addition of organocopper species to 3-[(E)-4,4,4-trifluorobut-2-enoyl] oxazolidin-2-ones. J. Fluorine Chem. 97, 91-96 (1999).
73. Cai C, Soloshonok VA, Hruby VJ. Michael addition reactions between chiral Ni(II) complex of glycine and 3-(trans-enoyl) oxazolidin-2-ones. A case of electron donor-acceptor attractive interactionscontrolled face diastereoselectivity. J. Org. Chem. 66, 1339-1350 (2001).
74. Kobzev SV, Soloshonok VA, Galushko SV, Yagupolskii YL, Kukhar VP. Fluorinecontaining amino acids. VI. Acid-base properties of α- trifluoromethyl-α-amino acids. Zh. Obshch. Khim. 59, 909-912 (1989).
75. Soloshonok VA, Hayashi T. Gold(I)- catalyzed asymmetric aldol reaction of fluorinated benzaldehydes with α-isocyanoacetamide. Tetra. Asymm. 5, 1091-1094 (1994).
76. Tarver JE, Terranove KM, Joullie MM. Hetero-Diels-Alder and pyroglutamate approaches to (2S,4R)-2-methylamino-5- hydroxy-4-methylpentanoic acid. Tetrahedron 45, 10277-10284 (2004).
77. King FE, Kidd DAA. New synthesis of glutamine and of γ-dipeptides of glutamic acid from phthalylated intermediates. J. Chem. Soc. 3315-3319 (1949).
78. Krstenansky JL, del Rosario-Chow M, Currie BL. The synthesis of syn- and anti-2(S)-phthalimidomethyl-2,3,4,4α,7,7αhexahydro- 6-oxo-5H-pyrano[2,3-β]pyrroles as rigid β-bend peptide-mimetics. J. Heterocyclic Chem. 29, 707-711 (1992).
79. Sakaitani M, Ohfune Y. Syntheses and reactions of silyl carbamates. 1. Chemoselective transformation of amino protecting groups via tert-butyldimethylsilyl carbamates. J. Org. Chem. 55, 870-876 (1990).
80. Flaih N, Pharm-Huy C, Galons H. An expeditious synthesis of cyclic imides. Tetrahedron Lett. 40, 3697-3698 (1999).